PhosphoPlus® Ezh2 (Thr345) Antibody Duet #80780
Product Information
Kit Usage Information
Protocols
- 5246: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Leica® Bond™), Immunohistochemistry (Paraffin), Immunofluorescence, Immunofluorescence, Flow, ChIP Magnetic, Chromatin IP-seq, CUT&RUN Assay, CUT&Tag
- 45153: Western Blotting, Immunoprecipitation (Magnetic), ChIP Magnetic, Chromatin IP-seq, CUT&RUN Assay
Product Description
Background
The polycomb group (PcG) proteins are involved in maintaining the silenced state of several developmentally regulated genes and contribute to the maintenance of cell identity, cell cycle regulation, and oncogenesis (1,2). Enhancer of zeste homolog 2 (Ezh2), a member of this large protein family, contains four conserved regions including domain I, domain II, and a cysteine-rich amino acid stretch that precedes the carboxy-terminal SET domain (3). The SET domain has been linked with histone methyltransferase (HMTase) activity. Moreover, mammalian Ezh2 is a member of a histone deacetylase complex that functions in gene silencing, acting at the level of chromatin structure (4). Ezh2 complexes methylate histone H3 at Lys9 and 27 in vitro, which is thought to be involved in targeting transcriptional regulators to specific loci (5). Ezh2 is deregulated in various tumor types, and its role, both as a primary effector and as a mediator of tumorigenesis, has become a subject of increased interest (6).
Ezh2 was shown to be phosphorylated by cyclin-dependent kinase 1 (CDK1) at Thr345 and Thr487 in a cell cycle-dependent manner (7). It has also been shown that the ANCR long non-coding RNA potentiates the Ezh2-CDK1 interaction, leading to increased phosphorylation of Thr345 and Thr487 on Ezh2 and facilitating ubiquitination and subsequent degradation of this protein (8).
- Sellers, W.R. and Loda, M. (2002) Cancer Cell 2, 349-50.
- Visser, H.P. et al. (2001) Br J Haematol 112, 950-8.
- Chen, H. et al. (1996) Genomics 38, 30-7.
- Tonini, T. et al. (2004) Oncogene 23, 4930-7.
- Müller, J. et al. (2002) Cell 111, 197-208.
- Kleer, C.G. et al. (2003) Proc Natl Acad Sci U S A 100, 11606-11.
- Kaneko, S. et al. (2010) Genes Dev 24, 2615-20.
- Li, Z. et al. (2017) Cell Death Differ 24, 59-71.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.